LUMENIS LTD More Aesthetic Practitioners Will be Able to Offer Their Patients the Latest Technology in Non-Ablative Skin Resurfacing
YOKNEAM, Israel, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (Nasdaq:LMNS), the world's largest energy-based medical company for aesthetic, surgical and ophthalmology applications, announced today the launch of the new ResurFX laser system for fractional non-ablative skin resurfacing treatments. This new ResurFX system is a stand-alone desktop solution with sleek design and user interface, which leverages on the superb technology and builds upon the successful launch of ResurFX module for the M22(TM) multi-application platform. The system debuts at the International Master Course on Aging Skin (IMCAS) Annual World Congress 2015, taking place in Paris, France from January 29 to February 1, 2015. Lumenis will be exhibiting at booth A11 throughout the meeting.
The new ResurFX system offers advanced features to improve efficacy and patient comfort, making it an ideal addition for each practice wanting to expand its non-ablative treatment offering. Lumenis' CoolScan(TM) technology ensures precise and safe energy delivery with continuous contact cooling, while the ResurFX system's customized treatment parameters allow aesthetic professionals to choose from more than 600 combinations of shape, size, density and energy delivery, and customize their treatments. Unlike other fractional technologies, ResurFX needs only one pass to be effective, saving practices time and protecting the patient's skin. With no disposables, the new ResurFX is also cost-effective for growing practices.
This extension of our offerings in the field of skin resurfacing will allow physicians to choose the best solution for their practice:
- A full multi application M22 platform with ResurFX, which also features the Lumenis Gold Standard IPL with OPT, Long Pulsed Nd:YAG and Q-Switched Nd:YAG
- A stand-alone desktop version of the ResurFX with a compact sleek design and user interface
"We have seen such a dramatic rise in fractional non-ablative skin resurfacing because the procedure provides excellent results without the long downtime associated with other cosmetic procedures," said Dr. Matteo Tretti Clementoni of Istituto Dermatologico Europeo. "ResurFX is the leading solution in this space because it provides the best balance of efficacy and patient convenience - some of my patients are even coming in for ResurFX treatment as a 'lunch-time' skin rejuvenation procedure."
In addition to introducing the new ResurFX, Lumenis will also be participating in a lecture series for attendees at IMCAS. Lumenis CEO Tzipi Ozer-Armon will deliver a presentation about the growth in demand for aesthetic products and services in the Asia-Pacific market, particularly China.
"The growing middle class in China and our 20 years of operational experience in the market propelled our continuous double digit growth in the APAC region," said Ms. Ozer-Armon. "We are honored to be speaking about this topic at IMCAS and look forward to working with aesthetic professionals across the globe to bring the new ResurFX system to patients."
Key Lumenis Activities at the IMCAS Annual World Congress 2015
| Friday, January 30, 2015 | |
| 11:30 | Live Demonstration: Striae treatment with ResurFX fractional non-ablative laser |
| Led by Matteo Tretti Clementoni, M.D., and Gerd Kautz, M.D. | |
| Room 4, Session 44 | |
| 11:50 | Live Demonstration: Striae treatment with ResurFX fractional non-ablative laser |
| Led by Matteo Tretti Clementoni, M.D., and Gerd Kautz, M.D. | |
| Room 4, Session 44 | |
| 12:10 | Live Demonstration: Acne scar treatment with AcuPulse(TM) MultiMode(TM) CO2 laser |
| Led by Matteo Tretti Clementoni, M.D. | |
| Room 4, Session 44 | |
| 17:35 | Lecture: "Why is Asia and Particularly China a Driving Force in the Aesthetic Device Business?" |
| Speaker: Tzipi Ozer-Armon, Chief Executive Officer, Lumenis | |
| Room 1, Session 37 | |
| Saturday, January 31, 2015 | |
| 13:45 | Scientific Talk: Combination of IPL and non-ablative 1565nm fiber laser for facial rejuvenation |
| Led by Patricia Ortiz-Garcia, M.D. | |
| Room Video Paper Stage, Session Video Papers - Lasers and Energy Based Devices |
About Lumenis
Lumenis (Nasdaq:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. For more information visit: www.lumenis.com:
http://www.globenewswire.com/newsroom/ctr?d=10117408&l=9&a=www.lumenis.com&u=http%3A%2F%2Fwww.lumenis.com%2F
*The new ResurFX is pending CE mark and FDA clearance.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) Lumenis' ability to develop and bring to market new products, (2) Lumenis' ability to successfully complete any necessary or required clinical studies with its products, (3) Lumenis' ability to receive regulatory clearance or approval to market its products or changes in regulatory environment, (4) Lumenis' success in implementing its sales, marketing and manufacturing plans, (5) the level of adoption of Lumenis' products by medical practitioners and other customers, (6) the emergence of other products that may make Lumenis' products obsolete, (7) protection and validity of patents and other intellectual property rights, (8) the impact of currency exchange rates, (9) the effect of competition by other companies, (10) the outcome of significant litigation, (11) Lumenis' ability to obtain reimbursement for its product from government and commercial payors, (12) quarterly variations in operating results, (13) the possibility of armed conflict or civil or military unrest in Israel, (14) the impact of global economic conditions, (15) Lumenis' ability to successfully integrate acquired businesses, (16) changes and reforms in applicable healthcare laws and regulations, (17) quality issues and adverse events related to Lumenis' products, including events that could require Lumenis to recall products and impact its sales and net income, and (18) other risks and factors disclosed in Lumenis' filings with the U.S. Securities and Exchange Commission (the "SEC"), including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in Lumenis' Annual Report on Form 20-F for the year ended December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except to the extent expressly required under applicable law, Lumenis undertakes no obligation to release publicly any revisions or updates to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
CONTACT: For further information:
Mai Duong
Lazar Partners Ltd.
(646) 871-8492The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lumenis Ltd. via Globenewswire
